AQR Capital Management’s Verve Therapeutics VERV Stock Holding History

AQR Capital Management’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-171,820	Closed	-$1.93M	–	3602
2025 Q2	$1.93M	Sell	171,820 -201,387	-54%	-$1.15M	﹤0.01%	1797
2025 Q1	$1.71M	Buy	373,207 +340,143	+1,029%	+$2.28M	﹤0.01%	1700
2024 Q4	$186K	Sell	33,064 -42,737	-56%	-$241K	﹤0.01%	2683
2024 Q3	$367K	Sell	75,801 -19,770	-21%	-$115K	﹤0.01%	2301
2024 Q2	$466K	Buy	+95,571	New	+$601K	﹤0.01%	2078

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

AQR Capital Management's VERV Position: Q3 2025 in Review

AQR Capital Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 171,820 shares — an estimated $1.93M sold.

AQR Capital Management first reported a position in VERV in Q2 2024 and held it in 5 quarters. The position peaked at $1.93M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

AQR Capital Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
AQR Capital Management sold 171,820 Verve Therapeutics shares in Q3 2025, an estimated $1.93M.
AQR Capital Management first reported a position in Verve Therapeutics in Q2 2024 and held it in 5 quarters.
AQR Capital Management's Verve Therapeutics position peaked at $1.93M in Q2 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.